10
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      A Qualitative Study of the Experience of COVID-19 Patients in Burkina Faso

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          ABSTRACT.

          In Burkina Faso, the health system is characterized by systemic insufficient and antiquated health-care infrastructures. Consequently, few health-care establishments have the required resources to diagnose and manage patients with COVID-19, and fewer still have intensive care facilities for severely ill patients with COVID. Furthermore, there is a widespread scarcity of qualified health-care staff. The aim of this study was to explore the experiences of patients with COVID-19 who recovered after being cared for in Bobo Dioulasso and Ouagadougou. Using individual semistructured interviews, we performed a cross-sectional qualitative, descriptive study from June 12 to 30, 2020 with the aid of 13 well-educated patients who had survived COVID-19. The results reveal that prior to hospital admission, the main reason that prompted patients to seek care was onset of symptoms of COVID-19, regardless of whether they had been in contact with suspected or confirmed cases. Transmission was mainly believed to have occurred in the community, in the hospital, and during travel. Patient management was punctuated by frequent self-medication with medicinal plants or pharmaceutical drugs. The participants reported a negative perception of hospitalization or home-based management, with several forms of stigmatization, but a positive perception influenced by the satisfactory quality of management in health-care centers. This report of patient experiences could be helpful in improving the management of COVID-19 in Burkina Faso, both in the health-care setting and in home-based care.

          Related collections

          Most cited references37

          • Record: found
          • Abstract: found
          • Article: found

          Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Coronavirus Disease 2019 (COVID-19): A Perspective from China

            Abstract In December 2019, an outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection occurred in Wuhan, Hubei Province, China and spread across China and beyond. On February 12, 2020, WHO officially named the disease caused by the novel coronavirus as Coronavirus Disease 2019 (COVID-19). Since most COVID-19 infected patients were diagnosed with pneumonia and characteristic CT imaging patterns, radiological examinations have become vital in early diagnosis and assessment of disease course. To date, CT findings have been recommended as major evidence for clinical diagnosis of COVID-19 in Hubei, China. This review focuses on the etiology, epidemiology, and clinical symptoms of COVID-19, while highlighting the role of chest CT in prevention and disease control. A full translation of this article in Chinese is available in the supplement. - 请见䃼充资料阅读文章中文版∘
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21

              (2022)
              Background Mortality statistics are fundamental to public health decision making. Mortality varies by time and location, and its measurement is affected by well known biases that have been exacerbated during the COVID-19 pandemic. This paper aims to estimate excess mortality from the COVID-19 pandemic in 191 countries and territories, and 252 subnational units for selected countries, from Jan 1, 2020, to Dec 31, 2021. Methods All-cause mortality reports were collected for 74 countries and territories and 266 subnational locations (including 31 locations in low-income and middle-income countries) that had reported either weekly or monthly deaths from all causes during the pandemic in 2020 and 2021, and for up to 11 year previously. In addition, we obtained excess mortality data for 12 states in India. Excess mortality over time was calculated as observed mortality, after excluding data from periods affected by late registration and anomalies such as heat waves, minus expected mortality. Six models were used to estimate expected mortality; final estimates of expected mortality were based on an ensemble of these models. Ensemble weights were based on root mean squared errors derived from an out-of-sample predictive validity test. As mortality records are incomplete worldwide, we built a statistical model that predicted the excess mortality rate for locations and periods where all-cause mortality data were not available. We used least absolute shrinkage and selection operator (LASSO) regression as a variable selection mechanism and selected 15 covariates, including both covariates pertaining to the COVID-19 pandemic, such as seroprevalence, and to background population health metrics, such as the Healthcare Access and Quality Index, with direction of effects on excess mortality concordant with a meta-analysis by the US Centers for Disease Control and Prevention. With the selected best model, we ran a prediction process using 100 draws for each covariate and 100 draws of estimated coefficients and residuals, estimated from the regressions run at the draw level using draw-level input data on both excess mortality and covariates. Mean values and 95% uncertainty intervals were then generated at national, regional, and global levels. Out-of-sample predictive validity testing was done on the basis of our final model specification. Findings Although reported COVID-19 deaths between Jan 1, 2020, and Dec 31, 2021, totalled 5·94 million worldwide, we estimate that 18·2 million (95% uncertainty interval 17·1–19·6) people died worldwide because of the COVID-19 pandemic (as measured by excess mortality) over that period. The global all-age rate of excess mortality due to the COVID-19 pandemic was 120·3 deaths (113·1–129·3) per 100 000 of the population, and excess mortality rate exceeded 300 deaths per 100 000 of the population in 21 countries. The number of excess deaths due to COVID-19 was largest in the regions of south Asia, north Africa and the Middle East, and eastern Europe. At the country level, the highest numbers of cumulative excess deaths due to COVID-19 were estimated in India (4·07 million [3·71–4·36]), the USA (1·13 million [1·08–1·18]), Russia (1·07 million [1·06–1·08]), Mexico (798 000 [741 000–867 000]), Brazil (792 000 [730 000–847 000]), Indonesia (736 000 [594 000–955 000]), and Pakistan (664 000 [498 000–847 000]). Among these countries, the excess mortality rate was highest in Russia (374·6 deaths [369·7–378·4] per 100 000) and Mexico (325·1 [301·6–353·3] per 100 000), and was similar in Brazil (186·9 [172·2–199·8] per 100 000) and the USA (179·3 [170·7–187·5] per 100 000). Interpretation The full impact of the pandemic has been much greater than what is indicated by reported deaths due to COVID-19 alone. Strengthening death registration systems around the world, long understood to be crucial to global public health strategy, is necessary for improved monitoring of this pandemic and future pandemics. In addition, further research is warranted to help distinguish the proportion of excess mortality that was directly caused by SARS-CoV-2 infection and the changes in causes of death as an indirect consequence of the pandemic. Funding Bill & Melinda Gates Foundation, J Stanton, T Gillespie, and J and E Nordstrom
                Bookmark

                Author and article information

                Journal
                Am J Trop Med Hyg
                Am J Trop Med Hyg
                tpmd
                tropmed
                The American Journal of Tropical Medicine and Hygiene
                The American Society of Tropical Medicine and Hygiene
                0002-9637
                1476-1645
                18 December 2023
                January 2024
                18 December 2023
                : 110
                : 1
                : 170-178
                Affiliations
                [ 1 ]Institut des Sciences des Sociétés, Ouagadougou, Burkina Faso;
                [ 2 ]Centre Muraz, Bobo-Dioulasso, Burkina Faso;
                [ 3 ]Université Nazi Boni, Bobo-Dioulasso, Burkina Faso;
                [ 4 ]McGill University, Montréal, Canada;
                [ 5 ]Epidemiology and Quality of Life Research Unit, INSERM U1231, Georges François Leclerc Comprehensive Cancer Centre, Dijon, France;
                [ 6 ]Observatoire National de Santé Publique, Ouagadougou, Burkina Faso;
                [ 7 ]Institut de Recherche en Sciences de la Santé, Ouagadougou, Burkina Faso;
                [ 8 ]Institut Pasteur du Cambodge, Phnom Penh, Cambodia;
                [ 9 ]Centre Hospitalier Universitaires Sanou Souro, Bobo-Dioulasso, Burkina Faso;
                [ 10 ]Centre Hospitalier Universitaires Bogodogo, Ouagadougou, Burkina Faso;
                [ 11 ]Direction des Systèmes d’Information en Santé, Ouagadougou, Burkina Faso;
                [ 12 ]Institut de Recherche en Sciences de la Santé, Nanoro, Burkina Faso
                Author notes

                Financial support: This work was funded by the Agence Nationale de Recherches sur le Sida et les Hépatites Virales.

                Disclosure: This study was performed in compliance with ethical standards and was approved by the Ethics Committee for Health Research (Comité d’éthique pour la Recherche en Santé) of Burkina Faso (no. 2020-8-140). Only participants who provided informed consent participated, and the anonymity and confidentiality of the data were guaranteed by the adherence of researchers to the principles of professional secrecy.

                Authors’ addresses: Blahima Konaté, Institut des Sciences des Sociétés, Ouagadougou, Burkina Faso, and Centre Muraz, Bobo-Dioulasso, Burkina Faso, E-mail: kobla70@ 123456hotmail.com . Rachel Médah, Nongodo Firmin Kaboré, and Dramane Kania, Centre Muraz, Bobo-Dioulasso, 03 BP 7047 Ouagadougou 03 Rue Naaba Soundoufou, Burkina Faso, E-mails: medchel1@ 123456yahoo.fr , nongodo@ 123456yahoo.fr , and draka3703@ 123456yahoo.fr . Isidore Traoré, Centre Muraz, Bobo-Dioulasso, Burkina Faso, and Université Nazi Boni, Bobo-Dioulasso, Burkina Faso, E-mail: tiandiogo2002@ 123456yahoo.fr . Samiratou Ouedraogo, McGill University, Montréal, Canada, E-mail: samiratou.ouedraogo@ 123456mcgill.ca . Ariane Kamga Mamguem, Oumar Billa, and Tienhan Sandrine Dabakuyo-Yonli, Epidemiology and Quality of Life Research Unit, INSERM U1231, Georges François Leclerc Comprehensive Cancer Centre, Dijon, France, E-mails: amamguem@ 123456cgfl.fr , obilla@ 123456cgfl.fr , and sdabakuyo@ 123456cgfl.fr . Hermann Badolo, Observatoire National de Santé Publique, Ouagadougou, Burkina Faso, E-mail: badholobi@ 123456gmail.com . Esperance Ouédraogo, Institut de Recherche en Sciences de la Santé, Ouagadougou, Burkina Faso, E-mail: especoul@ 123456yahoo.fr . Nathalie de Rekeneire, Centre Muraz, Bobo-Dioulasso, Burkina Faso, and Agence nationale de recherches sur le sida et les hépatites virales-Maladies infectieuses émergentes, Bobo-Dioulasso, Burkina Faso, E-mail: derekeneiren@ 123456yahoo.com . Armel Poda, Université Nazi Boni, Bobo-Dioulasso, Burkina Faso, and Centre Hospitalier Universitaires Sanou Souro, Bobo-Dioulasso, Burkina Faso, E-mail: armelpoda@ 123456yahoo.fr . Arnaud Eric Diendéré, Centre Hospitalier Universitaires Bogodogo, Ouagadougou, Burkina Faso, E-mail: ericdiendere@ 123456yahoo.fr . Boukary Ouédraogo, Direction des Systèmes d’Information en Santé, Ouagadougou, Burkina Faso, E-mail: ouedbouks@ 123456gmail.com . Halidou Tinto, Centre Muraz, Bobo-Dioulasso, Burkina Faso, and Institut de Recherche en Sciences de la Santé, Nanoro, Burkina Faso, E-mail: halidoutinto@ 123456gmail.com .

                [* ]Address correspondence to Blahima Konaté, Institut des Sciences des Sociétés, Ouagadougou, Burkina Faso. E-mail: kobla70@ 123456hotmail.com
                Article
                tpmd220351
                10.4269/ajtmh.22-0351
                10793024
                38109766
                676cb994-24b5-4ca8-9721-4df09cf57061
                © The author(s)

                This is an open-access article distributed under the terms of the Creative Commons Attribution (CC-BY) License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

                History
                : 23 May 2022
                : 07 July 2023
                Page count
                Pages: 9
                Categories
                Research Article

                Infectious disease & Microbiology
                Infectious disease & Microbiology

                Comments

                Comment on this article